Hepion pharmaceuticals, inc. HEPA.US AI Analysis
BetaUS StockHealthcare
(No presentation for HEPA)
HEPA Value Score
3
24
15
Limited Growth
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
HEPA Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
Entry
Exit
The Backtest Result of HEPA from 2014-02-10 till Now
- -
- Cumulative Return
- -
- Annual Return
- -
- Volatility
- -
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from February, 2014 to July, 2025. (Total Trades: 0)
| HEPA | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | - | 48% | 58% |
| Avg Return | - | 46.7% | 60.7% |
| Avg Profit | - | 141.3% | 128.2% |
| Avg Loss | - | -40.3% | -31.9% |
| Avg Risk-Reward Ratio | - | 350.9% | 402.1% |